Overview: KinetiSol Technology from AustinPx
The KinetiSol™ Technology generates amorphous solid dispersions, dramatically improving the bioavailability of poorly soluble drugs. KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies – in a fraction of the time of other ASD technologies. With its significantly smaller ecological footprint, broader formulation design space, faster processing times and wider application to…
Read MoreOvercoming Late Stage Formulations & Manufacturing Challenges with KinetiSol Technology
In this Xtalks webinar, Dr. Dave Miller, Chief Scientific Officer at AustinPx, explores how KinetiSol™ Technology helps sponsors overcome the formulation and manufacturing hurdles that often appear late in development. Traditional spray drying methods can introduce variability, high costs, and scale-up challenges, but KinetiSol offers a solvent-free alternative that delivers consistent performance and improved manufacturability.…
Read MoreOptimizing Amorphous Solid Dispersions: Overcoming Scale-Up Challenges with Next-Generation Technologies
As the number of poorly soluble molecules entering the pipeline has increased, the application of amorphous solid dispersions development has grown. With the advent of next-generation ASD technologies, like KinetiSol Technology, drug developers are setting new standards in scalability, sustainability and performance. In this webinar, the expert speakers will share their scale-up experiences and perspectives on opportunities to…
Read MoreWhy KinetiSol Technology is Disrupting Spray Drying
Dave Miller, AustinPx CSO’s (Chief Scientific Officer) talk begins by showcasing two case studies of commercial spray dried dispersions— replicated with KinetiSol and eliminating toxic solvents, manufacturing complexity, and improving drug product properties. Springboarding from these case studies, Dave then focuses on the facility, utilities, and downstream processing requirements for SDDs and contrasts those with…
Read MoreLess Mess, Less Stress, Best Expressed: A Superior Alternative To Spray Drying
In a recent article, Chris Brough, CTO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Unlike spray drying, which relies on organic solvents and nitrogen, KinetiSol uses a solvent-free process that directly dissolves drugs in polymers, preventing phase separation and enhancing stability and bioavailability. KinetiSol streamlines the scale-up…
Read MorePharma Matters Q&A: AustinPx, Talking Next-Gen Amorphous Dispersion Technology
Dave Miller, Chief Scientific Officer of AustinPx, discusses in a recent Q&A why our innovative KinetiSol Technology will revolutionize amorphous solid dispersions (ASDs) for poorly soluble APIs. Unlike traditional spray drying, KinetiSol uses a solvent-free process, enhancing stability and bioavailability by preventing phase separation and directly dissolving drugs in polymers. Miller explains how KinetiSol supports sustainable manufacturing…
Read MoreHow Prioritizing Sustainability Efforts Yields Long-term Growth in Drug Manufacturing
Pharmaceutical companies that invest strategically in sustainability initiatives will differentiate themselves in a competitive market. Implementing these practices ensures a robust and long-term market position, enabling stakeholders across the value chain to overcome post-COVID challenges, innovate, and secure a more sustainable future for the industry. With KinetiSol Technology, drug developers have a better option for developing…
Read MoreHow Sustainable Practices in Pharma Drive Long-term Growth
Embracing sustainability is not just socially responsible but also strategically beneficial, driving long-term financial returns and strengthening relationships with patients and the broader community. At AustinPx, sustainability, innovation, and client-centricity are our pillars as a CDMO. Our KinetiSol Technology doesn’t just offer a more sustainable method for developing poorly soluble drug candidates, it provides improved performance, accelerated…
Read MoreDCAT Sustainability Leaders (eBook)
The first edition of The Sustainability Leaders, an eBook presented by DCAT, is now available. AustinPx is one of the sustainability leaders highlighted in this eBook, as well as the efforts of other DCAT Member Companies that are contributing positively to the environment. You shouldn’t miss this opportunity to discover the praiseworthy initiatives being taken…
Read MoreConverting from a Spray-Dried Dispersion to a KinetiSol Formulation in <5 Months
A Phase 2 oral drug candidate formulated as a spray-dried dispersion faced limitations in bioavailability, pill burden, and solvent-intensive manufacturing. In less than five months, AustinPx converted the program to a KinetiSol™ formulation, achieving a 5x increase in AUC, reducing manufacturing time by 67%, and eliminating organic solvents and secondary processing steps. The result was…
Read MoreRedefining Drug-Like Properties with KinetiSol
Christopher Lipinski’s Rule of Five (Ro5) has been used for nearly three decades to evaluate whether a compound possesses the chemical and physical properties to potentially be an orally active drug in humans. But have modern molecules and technologies rendered Lipinski’s guidelines irrelevant? The KinetiSol process accommodates high-temperature melters without issue and solvent solubility is irrelevant to…
Read MoreKinetiSol in Action: Scalable, Sustainable Amorphous Dispersion Manufacturing
See the KinetiSol Compounder in action and learn how AustinPx’s proprietary KinetiSol™ Technology supports amorphous solid dispersion (ASD) development from rapid prototyping through commercial manufacturing. This video highlights how KinetiSol’s solvent-free, fusion-based process forms ASDs in seconds, simplifies scale-up, reduces operational burden, and expands the formulation design space for complex molecules. With a focus on scalability,…
Read MoreBeyond Solvents: The Future of Sustainable Amorphous Dispersion Development
AustinPx CEO Elizabeth Hickman examines why greener amorphous solid dispersion (ASD) development requires more than simply reducing solvent use. As sustainability expectations grow, she explains how cost, risk, timelines, and long-term asset value are all shaped by the complexity of the manufacturing process itself. The article explores how traditional solvent-based ASD approaches can introduce added…
Read MoreSustainability in Pharma Manufacturing: Strategic Benefits of Going Green
In this piece, AustinPx’s CEO, Elizabeth Hickman, explores how sustainability is becoming a strategic priority across the pharmaceutical supply chain. From renewable energy and waste reduction to IoT and blockchain-based transparency, companies are finding that going green is not just good for the planet, it improves supply chain resilience and profitability. Hickman highlights how CDMOs…
Read More